Compare SANDU PHARMA with - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SANDU PHARMA vs LAURUS LABS - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SANDU PHARMA LAURUS LABS SANDU PHARMA/
LAURUS LABS
 
P/E (TTM) x 23.2 33.2 70.0% View Chart
P/BV x 1.2 13.5 9.2% View Chart
Dividend Yield % 0.0 0.3 -  

Financials

 SANDU PHARMA   LAURUS LABS
EQUITY SHARE DATA
    SANDU PHARMA
Mar-20
LAURUS LABS
Mar-21
SANDU PHARMA/
LAURUS LABS
5-Yr Chart
Click to enlarge
High Rs27386 7.0%   
Low Rs1064 16.4%   
Sales per share (Unadj.) Rs68.389.7 76.2%  
Earnings per share (Unadj.) Rs1.018.3 5.5%  
Cash flow per share (Unadj.) Rs1.822.2 8.1%  
Dividends per share (Unadj.) Rs02.00 0.0%  
Avg Dividend yield %00.9 0.0%  
Book value per share (Unadj.) Rs41.348.3 85.5%  
Shares outstanding (eoy) m7.08536.60 1.3%   
Bonus / Rights / Conversions ---  
Price / Sales ratio x0.32.5 10.9%   
Avg P/E ratio x18.412.3 150.2%  
P/CF ratio (eoy) x10.410.1 102.7%  
Price / Book Value ratio x0.54.7 9.8%  
Dividend payout %010.9 0.0%   
Avg Mkt Cap Rs m133120,585 0.1%   
No. of employees `000NANA-   
Total wages/salary Rs m693,970 1.7%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m48448,135 1.0%  
Other income Rs m5237 1.9%   
Total revenues Rs m48848,372 1.0%   
Gross profit Rs m1515,507 0.1%  
Depreciation Rs m62,051 0.3%   
Interest Rs m4682 0.6%   
Profit before tax Rs m913,011 0.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m23,173 0.1%   
Profit after tax Rs m79,838 0.1%  
Gross profit margin %3.032.2 9.3%  
Effective tax rate %21.624.4 88.7%   
Net profit margin %1.520.4 7.3%  
BALANCE SHEET DATA
Current assets Rs m22430,749 0.7%   
Current liabilities Rs m11324,572 0.5%   
Net working cap to sales %22.912.8 178.7%  
Current ratio x2.01.3 158.1%  
Inventory Days Days1811 166.2%  
Debtors Days Days3510 356.7%  
Net fixed assets Rs m19026,758 0.7%   
Share capital Rs m711,073 6.6%   
"Free" reserves Rs m22224,853 0.9%   
Net worth Rs m29225,926 1.1%   
Long term debt Rs m04,292 0.0%   
Total assets Rs m41457,507 0.7%  
Interest coverage x3.120.1 15.5%   
Debt to equity ratio x00.2 0.0%  
Sales to assets ratio x1.20.8 139.5%   
Return on assets %2.818.3 15.2%  
Return on equity %2.537.9 6.5%  
Return on capital %4.645.3 10.2%  
Exports to sales %00-   
Imports to sales %034.4 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA16,560 0.0%   
Fx inflow Rs m033,250 0.0%   
Fx outflow Rs m016,560 0.0%   
Net fx Rs m016,690 0.0%   
CASH FLOW
From Operations Rs m627,330 0.8%  
From Investments Rs m-1-9,410 0.0%  
From Financial Activity Rs m-542,547 -2.1%  
Net Cashflow Rs m8468 1.6%  

Share Holding

Indian Promoters % 45.0 27.3 165.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 27.6 0.0%  
FIIs % 0.0 22.8 -  
ADR/GDR % 0.0 0.0 -  
Free float % 55.0 72.7 75.6%  
Shareholders   10,108 394,053 2.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SANDU PHARMA With:   CIPLA  BACIL PHARMA  FDC  GENNEX LAB.  LASA SUPERGENERICS  



Today's Market

Sensex Ends Above 61,000-Mark, Nifty Tops 18,300; Adani Ports, Wipro & Grasim Rally 5%(Closing)

Indian share markets witnessed positive trading activity throughout the day today and ended on a strong note.

Related Views on News

LAURUS LABS Announces Quarterly Results (1QFY22); Net Profit Up 40.7% (Quarterly Result Update)

Jul 31, 2021 | Updated on Jul 31, 2021

For the quarter ended June 2021, LAURUS LABS has posted a net profit of Rs 2 bn (up 40.7% YoY). Sales on the other hand came in at Rs 13 bn (up 31.2% YoY). Read on for a complete analysis of LAURUS LABS 's quarterly results.

More Views on News

Most Popular

Is it Time to Switch from Tata Power to NTPC?(Profit Hunter)

Oct 11, 2021

Given the huge run up in Tata Power, does it make sense to switch to NTPC?

This Proxy EV Stock Just got a Power Crisis Boost(Profit Hunter)

Oct 8, 2021

After months of research, I've come across few stocks that excite me far more than the mainstream electric vehicle companies.

Rs 1 Lakh Invested in These Cryptos at the Start of 2021 Became Rs...(Views On News)

Oct 8, 2021

These cryptos would have multiplied investors' wealth by as much as 10,000% in just nine months.

Top 5 'Digital India' Stocks(Views On News)

Oct 6, 2021

These companies are leading the Government's US$1 tn 'Digital India' initiative.

5 Exciting 'Unlisted' Companies and How to Play Them(Views On News)

Oct 7, 2021

Here's how you can invest in some of the most exciting start-ups of the decade.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SANDU PHARMA SHARE PRICE


Oct 14, 2021 (Close)

TRACK SANDU PHARMA

  • Track your investment in SANDU PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SANDU PHARMA 8-QTR ANALYSIS

COMPARE SANDU PHARMA WITH

MARKET STATS